Scientific deep-dive
Tirzepatide Week by Week: What the SURMOUNT Trials Recorded
The dose ladder takes months, not weeks. This sets out what SURMOUNT-1, 2 and 4 recorded at each stage on Zepbound and Mounjaro, and the roughly half of the lost weight that came back when people stopped.
Tirzepatide climbs a longer ladder than most people are told. The label starts at 2.5 mg and raises the dose no faster than every four weeks, so reaching the top of the range takes months, not weeks. In SURMOUNT-4, the trial built to test what continuing is worth, participants spent 36 weeks in open-label treatment before the real experiment started, losing about 20.9% along the way.[3] Here is what each SURMOUNT trial recorded, and what happened to the people who stopped.
The ladder comes first
Zepbound and Mounjaro both begin at 2.5 mg once weekly, and that opening dose is there to be tolerated rather than to work. Zepbound’s label is explicit that 2.5 mg is a starting dose only, with no approval as a dose to stay on. After four weeks the dose goes to 5 mg, and from there it can rise in 2.5 mg steps, each after at least four weeks on the current dose.[4] Zepbound and Mounjaro come in the same six strengths, from 2.5 mg to 15 mg; how much each maintenance dose delivered in the trials is set out in which Zepbound dose works best.
The practical consequence is that anyone measuring their progress in the first month or two is measuring the ladder, not the drug at its working dose. Our titration planner lays the schedule out against real dates from each label, and the Zepbound pen chart covers which strength is which.
If you buy compounded tirzepatide, the ladder can also have a price attached. BioGlow Health and GetRelief Rx charge more as the dose rises, and GetRelief sells only a daily under-the-tongue form, not a weekly injection. NoBsRx charges the same at any dose. StaveMD runs its plans on a four-week renewal, the same interval as each step on the label, while Novera MD shows the plan length behind its advertised figure only after a long intake.
Alan Meds also keeps one price at every dose, but the injectable compounded tirzepatide it lists is priced on a six-month plan paid up front. That is a long prepayment to weigh against a ladder whose upper steps you have not tried yet.
What 72 weeks produced
SURMOUNT-1 is the trial the rest are measured against. It enrolled 2,539 adults living with obesity and without diabetes and tested three doses (5, 10 and 15 mg) against placebo over 72 weeks. The top dose finished at −20.9% against −3.1% on placebo, and roughly 57% of that arm lost a fifth or more of their starting weight.[1]
That last figure deserves a closer look. More than half of the 15 mg arm reached a 20% loss or better, which also means a substantial minority did not, and some lost considerably less than the average. The mean describes a group and cannot predict one person’s result.
| Trial | Population | Duration | Result |
|---|---|---|---|
| SURMOUNT-1[1] | 2,539 adults with obesity, without diabetes | 72 weeks | −20.9% at 15 mg vs −3.1% placebo; ~57% lost ≥20% |
| SURMOUNT-2[2] | 938 adults with obesity and type 2 diabetes | 72 weeks | −14.7% at 15 mg and −12.8% at 10 mg vs −3.2%; A1C down about 2.1 points |
| SURMOUNT-4[3] | 670 people who had already lost about 20.9% | 36-week run-in, then 52 weeks | Continuers lost a further 5.5%; those switched to placebo gained 14.0% from their week-36 weight, ending 9.9% below where they started |
Diabetes changes the number
SURMOUNT-2 ran the same drug in people who had both excess weight and type 2 diabetes, and this is the population where GLP-1 drugs reliably underperform. Tirzepatide managed −14.7% at 15 mg and −12.8% at 10 mg against −3.2% on placebo, with A1C falling about 2.1 points.[2]
So roughly two-thirds to three-quarters of the effect seen without diabetes survives. If you have type 2 diabetes and have been comparing yourself against the 20.9% headline, you have been comparing yourself against the wrong trial.
What stopping did
SURMOUNT-4 is the clearest evidence on this question that exists for any GLP-1. Everyone in it first took tirzepatide openly for 36 weeks and lost about 20.9%. Then they were randomized: half continued, half moved to placebo, and both were followed for another year.
The continuers lost a further 5.5%. Those switched to placebo gained 14.0% of their week-36 weight. Measured from where everyone started, the placebo group ended the trial 9.9% lighter, against 25.3% for those who stayed on the drug.[3] By that arithmetic, about half of a 20.9% loss came back within a year, in people who had done everything the protocol asked of them. The paper itself calls it “substantial regain of lost weight.”
About half of a 20.9% loss came back within a year of switching to placebo.
Why this is not a race against semaglutide
It is tempting to set −20.9% beside semaglutide’s −14.9% and call it settled. That comparison is not available from these trials. SURMOUNT-1 and STEP 1 enrolled different people, ran for different lengths (72 weeks against 68), and each had its own placebo arm. Reading across two separate trials as though they were arms of one is the same move we criticize when a seller makes it.
A real head-to-head does exist. SURMOUNT-5 randomized 751 people between the two drugs, each at its own maximum tolerated dose, and tirzepatide produced 20.2% against 13.7% (see the head-to-head, and what it settles). Our semaglutide timeline sets out that drug’s own record on its own terms.
What this timeline cannot tell you
- Every figure is a group mean. Individuals scattered widely around each one, in both directions.
- Trial conditions are not ordinary conditions. Participants had free medication, structured support and regular contact with a study team.
- It describes the brand product at labeled doses. A compounded vial raises separate questions, taken up in is compounded tirzepatide safe.
- It says nothing about who should take it. That is a clinical judgment about your own history.
The support gap is one you can partly close yourself. Vaylen includes check-ins and safety labs in every plan, and Fitness RX lists labs, unlimited provider visits, coaching and nutrition support in its price, on a three-month minimum. Framework includes dietitian support, though it prices no plan, drug or dose before the health questions. Ivim Health sells compounded tirzepatide from $117 a month on a 12-month program, plus a $75 monthly program fee that covers unlimited provider visits and functional health coaches. None of that recreates a trial, but it is closer than a prescription with no follow-up.
One thing the published record does not settle: how much of the 36-week run-in loss in SURMOUNT-4 came from the dose ladder versus the maintenance dose that followed it. The trial reports the total, not the split, so the shape of that first stretch is less well described for tirzepatide than for semaglutide.
Frequently Asked Questions
References
- 1.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity New England Journal of Medicine. 2022. PMID: 35658024.
- 2.Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet. 2023. PMID: 37385275.
- 3.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. 2024. PMID: 38078870.
- 4.Eli Lilly and Company ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 2.1 dose escalation and Section 3 dosage forms and strengths DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Compare the sellers
Related research
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.
10 min read
Constipation on a GLP-1: What the Labels Report and What Actually Helps
The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. This explains why it outlasts the nausea and where the confident advice online runs ahead of the evidence.
6 min read
Joint Pain, Back Pain and Aches on a GLP-1: What the Trials Counted
No FDA label for these drugs lists joint or back pain, and in most trials both were about as common on placebo. The exception is the 7.2 mg Wegovy trial, and the one pain the labels do list is in the skin.
8 min read
GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning
Three of six GLP-1 labels warn about the contraceptive pill. Mounjaro and Zepbound set a four-week window after starting and after every dose increase, and Foundayo a 30-day one; the three semaglutide labels carry no such advisory. We read all six.
9 min read
Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip
Dizziness affects 4% to 8% of people on the weight-loss doses. The labels tell prescribers to lower insulin or sulfonylurea doses, and say nothing about blood-pressure pills, though low blood pressure is more common in people taking them.
7 min read
Why a GLP-1 Raises Your Heart Rate, and When Palpitations Matter
Every GLP-1 raises resting heart rate by a few beats a minute, but only Wegovy and Saxenda warn about it. What the labels show, why it happens, whether it matters, and the palpitations that point elsewhere.
9 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Collective
From $69/mo + membership
Get started →Wellorithm
From $349/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →